SCHEMBL14009117

SCHEMBL14009117

O=C(Nc1ccc(-n2cncn2)cc1)c1ccc(C(=O)Nc2ccccn2)s1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 11/20 0.52
▸ RAB9A P51151 11/20 0.52
▸ KMT2A Q03164 3/20 0.52
▸ MITF O75030 1/20 0.52
▸ KDM4E B2RXH2 3/20 0.47
▸ PPARG P37231 1/20 0.47
▸ NR2E3 Q9Y5X4 1/20 0.47
▸ NCOR2 Q9Y618 1/20 0.47
▸ ROCK1 Q13464 1/20 0.46
▸ SMN1; SMN2 Q16637 7/20 0.42
▸ USP2 O75604 1/20 0.42
▸ TP53 P04637 1/20 0.42
▸ LMNA P02545 1/20 0.41
▸ PKM P14618 2/20 0.40
▸ MEN1 O00255 2/20 0.40
▸ ADORA3 P0DMS8 1/20 0.40
▸ PIM1 P11309 1/20 0.40
▸ ADORA2A P29274 1/20 0.40
▸ ADORA2B P29275 1/20 0.40
▸ ADORA1 P30542 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14009163 0.87 ROCK1 (0.51) NPC1RAB9AKMT2AKDM4EPPARG
SCHEMBL14009123 0.85 HPGD (0.52) NPC1RAB9AKMT2AKDM4EPPARG
SCHEMBL14009145 0.84 NPC1 (0.55) NPC1RAB9AKMT2AKDM4ESMN1; SMN2
SCHEMBL14009070 0.84 RAB9A (0.51) NPC1RAB9AKMT2AKDM4EPPARG
SCHEMBL14009204 0.83 NAMPT (0.48) NPC1RAB9AKMT2AKDM4EPPARG
SCHEMBL14009172 0.83 RAB9A (0.47) NPC1RAB9AKMT2AROCK1SMN1; SMN2
SCHEMBL14009349 0.83 ROCK1 (0.46) NPC1RAB9AKMT2AKDM4EPPARG
SCHEMBL14609432 0.82 ROCK1 (0.45) NPC1RAB9AKMT2AKDM4EROCK1
SCHEMBL14609404 0.82 ROCK1 (0.45) NPC1RAB9AKMT2AKDM4EROCK1
SCHEMBL14009125 0.80 NPC1 (0.52) NPC1RAB9AKMT2AKDM4EROCK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7446195-B2 High affinity thiophene-based and furan-based kinase ligands SCHERING CORPORATION (US) 2008-11-04 — — US disclosed
US-7446195-B2 High affinity thiophene-based and furan-based kinase ligands SCHERING CORPORATION (US) 2008-11-04 — — US disclosed
US-20070043045-A1 Novel high affinity thiophene-based and furan-based kinase ligands SCHERING CORPORATION 2007-02-22 — — US disclosed
US-20070043045-A1 Novel high affinity thiophene-based and furan-based kinase ligands SCHERING CORPORATION 2007-02-22 — — US disclosed
WO-2007022258-A1 NOVEL HIGH AFFINITY THIOPHENE-BASED AND FURAN-BASED KINASE LIGANDS SCHERING CORPORATION (US) 2007-02-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043045-A1 Novel high affinity thiophene-based and furan-based kinase ligands CDKL2, CDK2, CDKL1 NPC1 4547/4885RAB9A 3846/4885KMT2A 806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback